|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
These results might suggest that Italian patients with SLE are, at least in part, different from lupus patients living in other geographical areas and suggest the association of DQw2 with the autoantibody response to ENA in SLE.
|
1954698 |
1991 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term follow-up studies with larger numbers of patients are necessary to evaluate the clinical significance of the presence of anti-dsDNA and anti-ENA antibodies in children infected with Human Immunodeficiency Virus.
|
7833557 |
1994 |
|
Mammary Neoplasms
|
0.030 |
AlteredExpression
|
group |
LHGDN |
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
|
16533770 |
2006 |
|
Colorectal Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We also performed immunohistochemical analysis of the expression of hMena protein in 50 cases of paraffin-embedded archival colorectal tissues, and found that an elevated hMena expression is correlated to the cases with advanced TNM stages of colorectal carcinomas (P<0.001).
|
19082477 |
2009 |
|
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression.
|
19082477 |
2009 |
|
IGA Glomerulonephritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The enabled homolog gene polymorphisms are associated with susceptibility and progression of childhood IgA nephropathy.
|
19641378 |
2009 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The candidate genes located at amplified regions of chromosomes or low-level gain regions such as PLA2G5 (1p36-p34), COL11A1 (1p21), KCNK2 (1q41), S100A3 (1q21), ENAH (1q42.12), RGS1 (1q31), KCNH1 (1q32-q41), INSIG2 (2q14.1), FGF12 (3q28), TRIO (5p15.2), RNASEN (5p15.2), FGF10 (5p13-p12), EDN1(6p24.1-p22.3), SULF1 (8q13.2-13.3), TLR4 (9q32-q33), TNC (9q33), NTRK2 (9q22.1), CD44 (11p13), NCAM1 (11q23.1), TRIM29 (11q22-q23), PAK1 (11q13-q14) and RAB27A (15q15-q21.1), are found to be associated with cellular migration and proliferation, tumor cell metastasis and invasion, anchorage independent growth and inhibition of apoptosis.
|
20083228 |
2010 |
|
Overlap syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since we have found HLA alleles typical both of systemic lupus erythematosus and Sjogren's syndrome, the persistence of ENA-SSA positivity was highly suspicious for a possible overlap syndrome.
|
20630136 |
2010 |
|
Heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunoblot analysis revealed significant upregulation of Mena protein expression in left ventricle tissue from patients with end-stage HF, calsequestrin-overexpressing mice, and isoproterenol-infused mice.
|
21335464 |
2011 |
|
Congestive heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunoblot analysis revealed significant upregulation of Mena protein expression in left ventricle tissue from patients with end-stage HF, calsequestrin-overexpressing mice, and isoproterenol-infused mice.
|
21335464 |
2011 |
|
Mammary Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors.
|
23129656 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
The presence of anti-ENA and anti-dsDNA autoantibodies in SLE patients was associated with elevated levels of TLR7 and TLR9 respectively.
|
23564191 |
2013 |
|
Tumor Cell Invasion
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
The possible role of Mena protein and its splicing-derived variants in embryogenesis, carcinogenesis, and tumor invasion: a systematic review of the literature.
|
23956979 |
2013 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Few recent studies have revealed that Mena protein could play a role in breast or pancreatic carcinogenesis.
|
23956979 |
2013 |
|
Lupus Erythematosus, Systemic
|
0.050 |
Biomarker
|
disease |
BEFREE |
Systemic lupus erythematosus (SLE) patients have anti-nuclear autoantibodies directed against dsDNA and RNA-associated antigens (extractable nuclear antigens; ENA).
|
24659206 |
2014 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The expression of Mena protein in 81 specimens of HCC tissues was determined by immunohistochemistry.
|
24683008 |
2014 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A typical sequencing study can easily generate hundreds of gigabytes of FASTQ files, while public archives such as ENA and NCBI and large international collaborations such as the Cancer Genome Atlas can accumulate many terabytes of data in this format.
|
24950811 |
2014 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
A typical sequencing study can easily generate hundreds of gigabytes of FASTQ files, while public archives such as ENA and NCBI and large international collaborations such as the Cancer Genome Atlas can accumulate many terabytes of data in this format.
|
24950811 |
2014 |
|
Stomach Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena protein reactivity.
|
25556597 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).
|
25670169 |
2015 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Loss of CLK2 in luminal breast cancer cells leads to the upregulation of epithelial-to-mesenchymal transition (EMT)-related genes and a switch to mesenchymal splice variants of several genes, including ENAH (MENA).
|
25670169 |
2015 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression of ENAH isoform 11a has been shown to be elevated in breast cancers that express HER2.
|
26149387 |
2015 |